Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma

ARX788 is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate with AS269 as cytotoxic payload. In this phase 1 multicenter dose-expansion clinical trial, patients with HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma failing to respond to prior tras...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yang, Qiu, Miao-Zhen, Wang, Ju-Feng, Zhang, Yan-Qiao, Shen, Ao, Yuan, Xiang-Lin, Zhang, Tao, Wei, Xiao-Li, Zhao, Hong-Yun, Wang, De-Shen, Zhao, Qi, Xiong, Gao-Zhun, Ji, Yan-Ping, Liang, Xue-Jun, Xia, Gang, Xu, Rui-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729820/
https://www.ncbi.nlm.nih.gov/pubmed/36384091
http://dx.doi.org/10.1016/j.xcrm.2022.100814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729820/
https://www.ncbi.nlm.nih.gov/pubmed/36384091
http://dx.doi.org/10.1016/j.xcrm.2022.100814

Ejemplares similares